Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 Aug;31(8):1340-54.
doi: 10.1016/j.neurobiolaging.2010.04.030. Epub 2010 Jun 8.

Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study

Affiliations
Comparative Study

Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study

Duygu Tosun et al. Neurobiol Aging. 2010 Aug.

Abstract

Previously it was reported that Alzheimer's disease (AD) patients have reduced beta amyloid (Abeta(1-42)) and elevated total tau (t-tau) and phosphorylated tau (p-tau(181p)) in the cerebrospinal fluid (CSF), suggesting that these same measures could be used to detect early AD pathology in healthy elderly individuals and those with mild cognitive impairment (MCI). In this study, we tested the hypothesis that there would be an association among rates of regional brain atrophy, the CSF biomarkers Abeta(1-42), t-tau, and p-tau(181p) and apolipoprotein E (ApoE) epsilon4 status, and that the pattern of this association would be diagnosis-specific. Our findings primarily showed that lower CSF Abeta(1-42) and higher tau concentrations were associated with increased rates of regional brain tissue loss and the patterns varied across the clinical groups. Taken together, these findings demonstrate that CSF biomarker concentrations are associated with the characteristic patterns of structural brain changes in healthy elderly and mild cognitive impairment subjects that resemble to a large extent the pathology seen in AD. Therefore, the finding of faster progression of brain atrophy in the presence of lower Abeta(1-42) levels and higher tau levels supports the hypothesis that CSF Abeta(1-42) and tau are measures of early AD pathology. Moreover, the relationship among CSF biomarkers, ApoE epsilon4 status, and brain atrophy rates are regionally varying, supporting the view that the genetic predisposition of the brain to beta amyloid and tau mediated pathology is regional and disease stage specific.

PubMed Disclaimer

Conflict of interest statement

Disclosure Statement: Dr. Tosun, Ms. Truran-Sacrey, Dr. Shaw, and Dr. Trojanowski report no disclosures.

Dr. Aisen has served as a consultant to Pfizer, Merck, and Novartis.

Dr. Schuff received honorary from the Michael J Fox foundation, the British Research Council and Elsevier Publishing company; receives research support from M.J. Fox foundation, Department of Defense (WX), P41 RR023953 (Coinvestigator); P50AG23501 (Coninvestigator).

Dr. Petersen serves as a consultant to Elan Pharmaceuticals, Wyeth Pharmaceuticals, and GE Healthcare; receives royalties from publishing Mild Cognitive Impairment (Oxford University Press, 2003); and receives research support from the NIA [AG 06786 (PI) and AG 16574 (PI)].

Dr. Weiner serves on scientific advisory boards for Bayer Schering Pharma, Eli Lilly, Nestle, CoMentis, Neurochem, Eisai, Avid, Aegis, Genentech, Allergan, Lippincott, Bristol Meyers Squibb, Forest, Pfizer, McKinsey, Mitsubishi, and Novartis. He has received non–industry-supported funding for travel; serves on the editorial board of Alzheimer's & Dementia; received honoraria from the Rotman Research Institute and BOLT International; receives research support from Merck & Co, Avid, NIH [U01AG024904 (PI), P41 RR023953 (PI), R01 AG10897 (PI), P01AG19724 (Coinvestigator), P50AG23501(Coinvestigator), R24 RR021992 (Coinvestigator), R01 NS031966 (Coinvestigator), and P01AG012435 (Coinvestigator)], the Department of Defense [DAMD17-01-1-0764 (PI)], and the Veterans Administration [MIRECC VISN 21 (Core PI)]; and holds stock in Synarc and Elan Pharmaceuticals.

Figures

Figure 1
Figure 1
Association between baseline CSF Aβ1-42 concentrations and absolute cortical thickness in CN group. [top row: cortical maps of regression coefficients βAβ1-42 from GLME models. bottom row: resulting FDR corrected p-value map from pair-wise ML F-tests.]
Figure 2
Figure 2
Top row: Distribution of effects of lower baseline CSF Aβ1-42 concentrations on higher rate of cortical thinning in MCI group, expressed in terms of a regression coefficient beta (in mm3/(year*pg/ul)). Bottom row: Also displayed are the corresponding significance maps (p-values, FDR corrected) derived from pair-wise maximum likelihood F-tests between GLME models with and without an interaction between biomarker concentration and atrophy rate.
Figure 3
Figure 3
Effects of baseline CSF p-tau181p concentrations on the rates of cortical atrophy in MCI group. [top row: cortical maps of regression coefficients βYears:p-tau181p from GLME models. bottom row: resulting FDR corrected p-value map from pair-wise ML F-tests.]
Figure 4
Figure 4
Effects of baseline CSF t-tau concentrations on rate of cortical atrophy in MCI group. [top row: cortical maps of regression coefficients βYears: t-tau from GLME models. bottom row: resulting FDR corrected p-value map from pair-wise ML F-tests.]

Similar articles

Cited by

References

    1. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE. Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly. Arch Neurol. 2008;65:1509–1517. - PMC - PubMed
    1. Andersson C, Blennow K, Johansson SE, Almkvist O, Engfeldt P, Lindau M, Eriksdotter-Jonhagen M. Differential CSF Biomarker Levels in APOE- e4-Positive and -Negative Patients with Memory Impairment. Dementia and Geriatric Cognitive Disorders. 2007;23:87–95. - PubMed
    1. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Blennow K. Cerebrospinal fluid tau and A[beta]42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neuroscience Letters. 1999;273:5–8. - PubMed
    1. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The Topographical and Neuroanatomical Distribution of Neurofibrillary Tangles and Neuritic Plaques in the Cerebral Cortex of Patients with Alzheimer's Disease. Cereb Cortex. 1991;1:103–116. - PubMed
    1. Basso M, Gelernter J, Yang J, MacAvoy MG, Varma P, Bronen RA, van Dyck CH. Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease. Neurobiology of Aging. 2006;27:1416–1424. - PubMed

Publication types

MeSH terms